Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

Guillermo Garcia-Manero*, Valeria Santini, Antonio Almeida, Uwe Platzbecker, Anna Jonasova, Lewis R. Silverman, Jose Falantes, Gianluigi Reda, Francesco Buccisano, Pierre Fenaux, Rena Buckstein, Maria Diez Campelo, Stephen Larsen, David Valcarcel, Paresh Vyas, Valentina Giai, Esther Natalie Oliva, Jake Shortt, Dietger Niederwieser, Moshe MittelmanLuana Fianchi, Ignazia La Torre, Jianhua Zhong, Eric Laille, Daniel Lopes De Menezes, Barry Skikne, C. L. Beach, Aristoteles Giagounidis

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes'. Together they form a unique fingerprint.

Medicine & Life Sciences